The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials

Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibitors. Ramucirumab, an anti-VEGFR2 antibody, has shown efficacy in GC, but the benefits are li...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Saeed, Anwaar, Park, Robin, Sun, Weijing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7802258/
https://ncbi.nlm.nih.gov/pubmed/33436042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01034-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller